Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

P-glycoprotein: from genomics to mechanism.

Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM.

Oncogene. 2003 Oct 20;22(47):7468-85. Review.

PMID:
14576852
2.

Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.

Zhou SF.

Xenobiotica. 2008 Jul;38(7-8):802-32. doi: 10.1080/00498250701867889 . Review.

PMID:
18668431
3.

Regulation and function of the multidrug resistance genes in liver.

Silverman JA, Thorgeirsson SS.

Prog Liver Dis. 1995;13:101-23. Review.

PMID:
9224499
4.

Reversal of multidrug resistance of tumor cells.

Szabó D, Keyzer H, Kaiser HE, Molnár J.

Anticancer Res. 2000 Nov-Dec;20(6B):4261-74. Review.

PMID:
11205256
5.

P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

Breier A, Barancík M, Sulová Z, Uhrík B.

Curr Cancer Drug Targets. 2005 Sep;5(6):457-68. Review.

PMID:
16178819
6.

P glycoprotein and the mechanism of multidrug resistance.

Váradi A, Szakács G, Bakos E, Sarkadi B.

Novartis Found Symp. 2002;243:54-65; discussion 65-8, 180-5. Review.

PMID:
11990782
8.

Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).

He SM, Li R, Kanwar JR, Zhou SF.

Curr Med Chem. 2011;18(3):439-81. Review.

PMID:
21143116
9.

Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp.

Molnár J, Kars MD, Gündüz U, Engi H, Schumacher U, Van Damme EJ, Peumans WJ, Makovitzky J, Gyémánt N, Molnár P.

Acta Histochem. 2009;111(4):329-33. doi: 10.1016/j.acthis.2008.11.010. Epub 2009 Jan 4.

PMID:
19124148
10.

Functional role of the linker region in purified human P-glycoprotein.

Sato T, Kodan A, Kimura Y, Ueda K, Nakatsu T, Kato H.

FEBS J. 2009 Jul;276(13):3504-16. doi: 10.1111/j.1742-4658.2009.07072.x. Epub 2009 May 21.

11.

Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?

Loo TW, Clarke DM.

Biochem Biophys Res Commun. 2005 Apr 8;329(2):419-22.

PMID:
15737603
12.

New horizon of MDR1 (P-glycoprotein) study.

Mizutani T, Hattori A.

Drug Metab Rev. 2005;37(3):489-510. Review.

PMID:
16257832
13.

Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux.

Loo TW, Clarke DM.

J Membr Biol. 2005 Aug;206(3):173-85. Review.

PMID:
16456713
14.

Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.

Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y.

Cancer Sci. 2006 Nov;97(11):1198-204. Epub 2006 Aug 22.

15.

A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein.

Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, Sugimoto Y.

Mol Cancer Ther. 2006 Apr;5(4):877-84.

16.
17.

Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.

Bansal T, Jaggi M, Khar RK, Talegaonkar S.

J Pharm Pharm Sci. 2009;12(1):46-78.

18.

Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein.

Srinivas E, Murthy JN, Rao AR, Sastry GN.

Curr Drug Metab. 2006 Feb;7(2):205-17. Review.

PMID:
16472108
19.

Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.

Battisti RF, Zhong Y, Fang L, Gibbs S, Shen J, Nadas J, Zhang G, Sun D.

Mol Pharm. 2007 Jan-Feb;4(1):140-53.

PMID:
17274671
20.

Pharmacological strategies for overcoming multidrug resistance.

Nobili S, Landini I, Giglioni B, Mini E.

Curr Drug Targets. 2006 Jul;7(7):861-79. Review.

PMID:
16842217

Supplemental Content

Support Center